Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
Spain
Hospital Universitari Vall Hebrón, Barcelona Hospital Universitari i Politecnic La Fe, Valencia United Kingdom
Addenbrookes Hospital, Cambridge University College London Hospitals NHS Foundation Trust, London Great Ormond Street Hospital, London Manchester Royal Infirmary, Manchester University NHS Foundation Trust,, Manchester